{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T18:39:04Z","timestamp":1794335944488,"version":"4.9.0"},"reference-count":126,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,23]],"date-time":"2025-08-23T00:00:00Z","timestamp":1755907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,8,23]],"date-time":"2025-08-23T00:00:00Z","timestamp":1755907200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01DK137980"],"award-info":[{"award-number":["R01DK137980"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Transpl Rep"],"DOI":"10.1007\/s40472-025-00489-1","type":"journal-article","created":{"date-parts":[[2025,8,23]],"date-time":"2025-08-23T08:25:29Z","timestamp":1755937529000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Cellular Therapies in Transplantation \u2013 Regulatory T Cell Therapies and Virus Specific Therapies"],"prefix":"10.1007","volume":"12","author":[{"given":"Zein Alabdin","family":"Hannouneh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massini","family":"Merzkani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chyi-Song","family":"Hsieh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoka","family":"Murakami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,23]]},"reference":[{"key":"489_CR1","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1111\/j.1600-6143.2011.03686.x","volume":"11","author":"M Tonelli","year":"2011","unstructured":"Tonelli M, Wiebe N, Knoll G, Bello A, Browne S, Jadhav D, Klarenbach S, Gill J. Systematic review: kidney transplantation compared with Dialysis in clinically relevant outcomes. Am J Transpl. 2011;11:2093\u2013109.","journal-title":"Am J Transpl"},{"key":"489_CR2","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1111\/j.1440-1797.2008.01073.x","volume":"14","author":"K Howard","year":"2009","unstructured":"Howard K, Salkeld G, White S, McDonald S, Chadban S, Craig JC, Cass A. The cost-effectiveness of increasing kidney transplantation and home-based Dialysis. Nephrol (Carlton). 2009;14:123\u201332.","journal-title":"Nephrol (Carlton)"},{"key":"489_CR3","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.4049\/jimmunol.155.3.1151","volume":"155","author":"S Sakaguchi","year":"1995","unstructured":"Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol. 1995;155:1151\u201364.","journal-title":"J Immunol"},{"key":"489_CR4","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1097\/00002281-200307000-00010","volume":"15","author":"E Gambineri","year":"2003","unstructured":"Gambineri E, Torgerson TR, Ochs HD. Immune dysregulation, polyendocrinopathy, enteropathy, and X-linked inheritance (IPEX), a syndrome of systemic autoimmunity caused by mutations of FOXP3, a critical regulator of T-cell homeostasis. Curr Opin Rheumatol. 2003;15:430\u20135.","journal-title":"Curr Opin Rheumatol"},{"key":"489_CR5","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1038\/ni904","volume":"4","author":"JD Fontenot","year":"2003","unstructured":"Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD4 + CD25 + regulatory T cells. Nat Immunol. 2003;4:330\u20136.","journal-title":"Nat Immunol"},{"key":"489_CR6","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1007\/s00018-009-0026-2","volume":"66","author":"CJ Workman","year":"2009","unstructured":"Workman CJ, Szymczak-Workman AL, Collison LW, Pillai MR, Vignali DAA. The development and function of regulatory T cells. Cell Mol Life Sci. 2009;66:2603\u201322.","journal-title":"Cell Mol Life Sci"},{"key":"489_CR7","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1002\/lt.20612","volume":"12","author":"A Demirkiran","year":"2006","unstructured":"Demirkiran A, Kok A, Kwekkeboom J, Kusters JG, Metselaar HJ, van der Tilanus HW. Low Circulating regulatory T-cell levels after acute rejection in liver transplantation. Liver Transpl. 2006;12:277\u201384.","journal-title":"Liver Transpl"},{"key":"489_CR8","doi-asserted-by":"publisher","first-page":"5813","DOI":"10.4049\/jimmunol.161.11.5813","volume":"161","author":"MP Wise","year":"1998","unstructured":"Wise MP, Bemelman F, Cobbold SP, Waldmann H. Cutting edge: linked suppression of skin graft rejection can operate through indirect Recognition1. J Immunol. 1998;161:5813\u20136.","journal-title":"J Immunol"},{"key":"489_CR9","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1172\/JCI82771","volume":"126","author":"KG MacDonald","year":"2016","unstructured":"MacDonald KG, Hoeppli RE, Huang Q, Gillies J, Luciani DS, Orban PC, Broady R, Levings MK. Alloantigen-specific regulatory T cells generated with a chimeric antigen receptor. J Clin Invest. 2016;126:1413\u201324.","journal-title":"J Clin Invest"},{"key":"489_CR10","doi-asserted-by":"publisher","first-page":"e160674","DOI":"10.1172\/jci.insight.160674","volume":"7","author":"S Bolivar-Wagers","year":"2022","unstructured":"Bolivar-Wagers S, Loschi ML, Jin S, et al. Murine CAR19 Tregs suppress acute graft-versus-host disease and maintain graft-versus-tumor responses. JCI Insight. 2022;7:e160674.","journal-title":"JCI Insight"},{"key":"489_CR11","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1084\/jem.20041982","volume":"201","author":"R Setoguchi","year":"2005","unstructured":"Setoguchi R, Hori S, Takahashi T, Sakaguchi S. Homeostatic maintenance of natural Foxp3(+) CD25(+) CD4(+) regulatory T cells by Interleukin (IL)-2 and induction of autoimmune disease by IL-2 neutralization. J Exp Med. 2005;201:723\u201335.","journal-title":"J Exp Med"},{"key":"489_CR12","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.147474","author":"S Dong","year":"2021","unstructured":"Dong S, Hiam-Galvez KJ, Mowery CT, et al. The effect of low-dose IL-2 and Treg adoptive cell therapy in patients with type 1 diabetes. JCI Insight. 2021. https:\/\/doi.org\/10.1172\/jci.insight.147474.","journal-title":"JCI Insight"},{"key":"489_CR13","doi-asserted-by":"publisher","first-page":"2067","DOI":"10.1056\/NEJMoa1105143","volume":"365","author":"D Saadoun","year":"2011","unstructured":"Saadoun D, Rosenzwajg M, Joly F, Six A, Carrat F, Thibault V, Sene D, Cacoub P, Klatzmann D. Regulatory T-cell responses to low-dose interleukin-2 in HCV-induced vasculitis. N Engl J Med. 2011;365:2067\u201377.","journal-title":"N Engl J Med"},{"key":"489_CR14","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1056\/NEJMoa1108188","volume":"365","author":"J Koreth","year":"2011","unstructured":"Koreth J, Matsuoka K, Kim HT, et al. Interleukin-2 and regulatory T cells in Graft-versus-Host disease. N Engl J Med. 2011;365:2055\u201366.","journal-title":"N Engl J Med"},{"key":"489_CR15","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1136\/annrheumdis-2019-215396","volume":"79","author":"J He","year":"2020","unstructured":"He J, Zhang R, Shao M, et al. Efficacy and safety of low-dose IL-2 in the treatment of systemic lupus erythematosus: a randomised, double-blind, placebo-controlled trial. Ann Rheum Dis. 2020;79:141\u20139.","journal-title":"Ann Rheum Dis"},{"key":"489_CR16","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.jhep.2022.08.035","volume":"78","author":"TY Lim","year":"2023","unstructured":"Lim TY, Perpi\u00f1\u00e1n E, Londo\u00f1o M-C, et al. Low dose interleukin-2 selectively expands Circulating regulatory T cells but fails to promote liver allograft tolerance in humans. J Hepatol. 2023;78:153\u201364.","journal-title":"J Hepatol"},{"key":"489_CR17","unstructured":"McGrath M, Tripathi S, Chandraker A. (2017) Risks [abstract]ssociated with Recombinant IL2 [abstract]herapy in [abstract]enal [abstract]ransplantation. [abstract]. ATC Abstracts 17."},{"key":"489_CR18","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.ajt.2023.01.016","volume":"23","author":"N Murakami","year":"2023","unstructured":"Murakami N, Borges TJ, Win TS, et al. Low-dose interleukin-2 promotes immune regulation in face transplantation: A pilot study. Am J Transpl. 2023;23:549\u201358.","journal-title":"Am J Transpl"},{"key":"489_CR19","doi-asserted-by":"publisher","first-page":"eaba5264","DOI":"10.1126\/sciimmunol.aba5264","volume":"5","author":"L Khoryati","year":"2020","unstructured":"Khoryati L, Pham MN, Sherve M, Kumari S, Cook K, Pearson J, Bogdani M, Campbell DJ, Gavin MA. An IL-2 Mutein engineered to promote expansion of regulatory T cells arrests ongoing autoimmunity in mice. Sci Immunol. 2020;5:eaba5264.","journal-title":"Sci Immunol"},{"key":"489_CR20","doi-asserted-by":"publisher","first-page":"e173107","DOI":"10.1172\/JCI173107","volume":"134","author":"O Efe","year":"2024","unstructured":"Efe O, Gassen RB, Morena L, et al. A humanized IL-2 Mutein expands Tregs and prolongs transplant survival in preclinical models. J Clin Invest. 2024;134:e173107.","journal-title":"J Clin Invest"},{"key":"489_CR21","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1038\/mt.sj.6300134","volume":"15","author":"MM Suhoski","year":"2007","unstructured":"Suhoski MM, Golovina TN, Aqui NA, Tai VC, Varela-Rohena A, Milone MC, Carroll RG, Riley JL, June CH. Engineering artificial antigen-presenting cells to express a diverse array of co-stimulatory molecules. Mol Ther. 2007;15:981\u20138.","journal-title":"Mol Ther"},{"key":"489_CR22","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1093\/cei\/uxac078","volume":"211","author":"O McCallion","year":"2022","unstructured":"McCallion O, Bilici M, Hester J, Issa F. Regulatory T-cell therapy approaches. Clin Exp Immunol. 2022;211:96\u2013107.","journal-title":"Clin Exp Immunol"},{"key":"489_CR23","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1016\/S0140-6736(20)30167-7","volume":"395","author":"B Sawitzki","year":"2020","unstructured":"Sawitzki B, Harden PN, Reinke P, et al. Regulatory cell therapy in kidney transplantation (The ONE Study): a harmonised design and analysis of seven non-randomised, single-arm, phase 1\/2A trials. Lancet. 2020;395:1627\u201339.","journal-title":"Lancet"},{"key":"489_CR24","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.744763","author":"J Balcerek","year":"2021","unstructured":"Balcerek J, Shy BR, Putnam AL, et al. Polyclonal regulatory T cell manufacturing under cGMP: A decade of experience. Front Immunol. 2021. https:\/\/doi.org\/10.3389\/fimmu.2021.744763.","journal-title":"Front Immunol"},{"key":"489_CR25","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.omtm.2018.01.006","volume":"8","author":"H Fraser","year":"2018","unstructured":"Fraser H, Safinia N, Grageda N, et al. A Rapamycin-Based GMP-Compatible process for the isolation and expansion of regulatory T cells for clinical trials. Mol Therapy - Methods Clin Dev. 2018;8:198\u2013209.","journal-title":"Mol Therapy - Methods Clin Dev"},{"key":"489_CR26","doi-asserted-by":"publisher","first-page":"315ra189","DOI":"10.1126\/scitranslmed.aad4134","volume":"7","author":"JA Bluestone","year":"2015","unstructured":"Bluestone JA, Buckner JH, Fitch M, et al. Type 1 diabetes immunotherapy using polyclonal regulatory T cells. Sci Transl Med. 2015;7:315ra189.","journal-title":"Sci Transl Med"},{"key":"489_CR27","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1182\/blood-2010-07-293795","volume":"117","author":"CG Brunstein","year":"2011","unstructured":"Brunstein CG, Miller JS, Cao Q, et al. Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics. Blood. 2011;117:1061\u201370.","journal-title":"Blood"},{"key":"489_CR28","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.clim.2009.06.001","volume":"133","author":"P Trzonkowski","year":"2009","unstructured":"Trzonkowski P, Bieniaszewska M, Ju\u015bci\u0144ska J, Dobyszuk A, Krzystyniak A, Marek N, My\u015bliwska J, Hellmann A. First-in-man clinical results of the treatment of patients with graft versus host disease with human ex vivo expanded CD4 + CD25 + CD127- T regulatory cells. Clin Immunol. 2009;133:22\u20136.","journal-title":"Clin Immunol"},{"key":"489_CR29","doi-asserted-by":"publisher","first-page":"7428","DOI":"10.1038\/s41598-018-25574-7","volume":"8","author":"JM Mathew","year":"2018","unstructured":"Mathew JM, H.-Voss J, LeFever A, et al. A phase I clinical trial with ex vivo expanded recipient regulatory T cells in living donor kidney transplants. Sci Rep. 2018;8:7428.","journal-title":"Sci Rep"},{"key":"489_CR30","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1097\/TP.0b013e318200e97","volume":"91","author":"J Levitsky","year":"2011","unstructured":"Levitsky J, Gallon L, Miller J, Tambur AR, Leventhal J, Flaa C, Huang X, Sarraj B, Wang E, Mathew JM. Allospecific regulatory effects of sirolimus and tacrolimus in the human mixed lymphocyte reaction. Transplantation. 2011;91:199\u2013206.","journal-title":"Transplantation"},{"key":"489_CR31","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.1097\/TP.0000000000000717","volume":"99","author":"L Gallon","year":"2015","unstructured":"Gallon L, Traitanon O, Yu Y, Shi B, Leventhal JR, Miller J, Mas V, Mathew LX JM. Differential effects of calcineurin and mammalian target of Rapamycin inhibitors on alloreactive Th1, Th17, and regulatory T cells. Transplantation. 2015;99:1774\u201384.","journal-title":"Transplantation"},{"key":"489_CR32","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1111\/ajt.15700","volume":"20","author":"A S\u00e1nchez-Fueyo","year":"2020","unstructured":"S\u00e1nchez-Fueyo A, Whitehouse G, Grageda N, et al. Applicability, safety, and biological activity of regulatory T cell therapy in liver transplantation. Am J Transplant. 2020;20:1125\u201336.","journal-title":"Am J Transplant"},{"key":"489_CR33","doi-asserted-by":"publisher","first-page":"2945","DOI":"10.1111\/ajt.14415","volume":"17","author":"S Chandran","year":"2017","unstructured":"Chandran S, Tang Q, Sarwal M, et al. Polyclonal regulatory T cell therapy for control of inflammation in kidney transplants. Am J Transpl. 2017;17:2945\u201354.","journal-title":"Am J Transpl"},{"key":"489_CR34","doi-asserted-by":"publisher","first-page":"m3734","DOI":"10.1136\/bmj.m3734","volume":"371","author":"A Roemhild","year":"2020","unstructured":"Roemhild A, Otto NM, Moll G, et al. Regulatory T cells for minimising immune suppression in kidney transplantation: phase i\/iia clinical trial. BMJ. 2020;371:m3734.","journal-title":"BMJ"},{"key":"489_CR35","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1002\/hep.28459","volume":"64","author":"S Todo","year":"2016","unstructured":"Todo S, Yamashita K, Goto R, et al. A pilot study of operational tolerance with a regulatory T-cell\u2010based cell therapy in living donor liver transplantation. Hepatology. 2016;64:632.","journal-title":"Hepatology"},{"key":"489_CR36","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1111\/ajt.16395","volume":"21","author":"PN Harden","year":"2021","unstructured":"Harden PN, Game DS, Sawitzki B, et al. Feasibility, long-term safety, and immune monitoring of regulatory T cell therapy in living donor kidney transplant recipients. Am J Transpl. 2021;21:1603\u201311.","journal-title":"Am J Transpl"},{"key":"489_CR37","doi-asserted-by":"publisher","first-page":"eabo2628","DOI":"10.1126\/scitranslmed.abo2628","volume":"14","author":"Q Tang","year":"2022","unstructured":"Tang Q, Leung J, Peng Y, et al. Selective decrease of donor-reactive Tregs after liver transplantation limits Treg therapy for promoting allograft tolerance in humans. Sci Transl Med. 2022;14:eabo2628.","journal-title":"Sci Transl Med"},{"key":"489_CR38","doi-asserted-by":"publisher","first-page":"1872","DOI":"10.1016\/j.ajt.2023.06.012","volume":"23","author":"EC Guinan","year":"2023","unstructured":"Guinan EC, Contreras-Ruiz L, Crisalli K, et al. Donor antigen-specific regulatory T cell administration to recipients of live donor kidneys: A ONE study consortium pilot trial. Am J Transplant. 2023;23:1872\u201381.","journal-title":"Am J Transplant"},{"key":"489_CR39","doi-asserted-by":"publisher","first-page":"2897","DOI":"10.1182\/bloodadvances.2021006309","volume":"6","author":"JD Rubinstein","year":"2022","unstructured":"Rubinstein JD, Lutzko C, Leemhuis T, et al. Scheduled administration of virus-specific T cells for viral prophylaxis after pediatric allogeneic stem cell transplant. Blood Adv. 2022;6:2897\u2013907.","journal-title":"Blood Adv"},{"key":"489_CR40","doi-asserted-by":"publisher","first-page":"2278","DOI":"10.1097\/TP.0000000000005065","volume":"108","author":"MO Brook","year":"2024","unstructured":"Brook MO, Hennessy C, Hester J, et al. Late treatment with autologous expanded regulatory T-cell therapy after alemtuzumab induction is safe and facilitates immunosuppression minimization in living donor renal transplantation. Transplantation. 2024;108:2278.","journal-title":"Transplantation"},{"key":"489_CR41","doi-asserted-by":"publisher","first-page":"e061864","DOI":"10.1136\/bmjopen-2022-061864","volume":"12","author":"MO Brook","year":"2022","unstructured":"Brook MO, Hester J, Petchey W, et al. Transplantation without overimmunosuppression (TWO) study protocol: a phase 2b randomised controlled single-centre trial of regulatory T cell therapy to facilitate immunosuppression reduction in living donor kidney transplant recipients. BMJ Open. 2022;12:e061864.","journal-title":"BMJ Open"},{"key":"489_CR42","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1097\/MNH.0000000000000737","volume":"30","author":"S Leclerc","year":"2021","unstructured":"Leclerc S, Lamarche C. Cellular therapies in kidney transplantation. Curr Opin Nephrol Hypertens. 2021;30:584.","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"489_CR43","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1038\/ni.1774","volume":"10","author":"X Zhou","year":"2009","unstructured":"Zhou X, Bailey-Bucktrout S, Jeker LT, Penaranda C, Mart\u00ednez-Llordella M, Ashby M, Nakayama M, Rosenthal W, Bluestone JA. Foxp3 instability leads to the generation of pathogenic memory T cells in vivo. Nat Immunol. 2009;10:1000\u20137.","journal-title":"Nat Immunol"},{"key":"489_CR44","doi-asserted-by":"publisher","first-page":"215ra174","DOI":"10.1126\/scitranslmed.3007320","volume":"5","author":"L Passerini","year":"2013","unstructured":"Passerini L, Rossi Mel E, Sartirana C, Fousteri G, Bondanza A, Naldini L, Roncarolo MG, Bacchetta R. CD4+ T cells from IPEX patients convert into functional and stable regulatory T cells by FOXP3 gene transfer. Sci Transl Med. 2013;5:215ra174.","journal-title":"Sci Transl Med"},{"key":"489_CR45","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1038\/sj.mt.6300341","volume":"16","author":"SE Allan","year":"2008","unstructured":"Allan SE, Alstad AN, Merindol N, Crellin NK, Amendola M, Bacchetta R, Naldini L, Roncarolo MG, Soudeyns H, Levings MK. Generation of potent and stable human CD4 + T regulatory cells by activation-independent expression of FOXP3. Mol Ther. 2008;16:194\u2013202.","journal-title":"Mol Ther"},{"key":"489_CR46","doi-asserted-by":"publisher","first-page":"eadl4793","DOI":"10.1126\/science.adl4793","volume":"386","author":"NR Reddy","year":"2024","unstructured":"Reddy NR, Maachi H, Xiao Y, et al. Engineering synthetic suppressor T cells that execute locally targeted immunoprotective programs. Science. 2024;386:eadl4793.","journal-title":"Science"},{"key":"489_CR47","doi-asserted-by":"publisher","first-page":"4247","DOI":"10.1182\/blood-2004-11-4564","volume":"105","author":"KC Straathof","year":"2005","unstructured":"Straathof KC, Pul\u00e8 MA, Yotnda P, Dotti G, Vanin EF, Brenner MK, Heslop HE, Spencer DM, Rooney CM. An inducible caspase 9 safety switch for T-cell therapy. Blood. 2005;105:4247\u201354.","journal-title":"Blood"},{"key":"489_CR48","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1182\/blood-2011-02-337360","volume":"118","author":"X Wang","year":"2011","unstructured":"Wang X, Chang W-C, Wong CW, Colcher D, Sherman M, Ostberg JR, Forman SJ, Riddell SR, Jensen MC. A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells. Blood. 2011;118:1255\u201363.","journal-title":"Blood"},{"key":"489_CR49","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1182\/blood-2014-01-545020","volume":"124","author":"B Philip","year":"2014","unstructured":"Philip B, Kokalaki E, Mekkaoui L, et al. A highly compact epitope-based marker\/suicide gene for easier and safer T-cell therapy. Blood. 2014;124:1277\u201387.","journal-title":"Blood"},{"key":"489_CR50","doi-asserted-by":"publisher","first-page":"ra8342","DOI":"10.1126\/scitranslmed.3002076","volume":"3","author":"P Sagoo","year":"2011","unstructured":"Sagoo P, Ali N, Garg G, Nestle FO, Lechler RI, Lombardi G. Human regulatory T cells with alloantigen specificity are more potent inhibitors of alloimmune skin graft damage than polyclonal regulatory T cells. Sci Transl Med. 2011;3:ra8342\u20138342.","journal-title":"Sci Transl Med"},{"key":"489_CR51","doi-asserted-by":"publisher","first-page":"3602","DOI":"10.4049\/jimmunol.156.10.3602","volume":"156","author":"JD Davies","year":"1996","unstructured":"Davies JD, Leong LY, Mellor A, Cobbold SP, Waldmann H. T cell suppression in transplantation tolerance through linked recognition. J Immunol. 1996;156:3602\u20137.","journal-title":"J Immunol"},{"key":"489_CR52","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1097\/00007890-199705270-00020","volume":"63","author":"W Wong","year":"1997","unstructured":"Wong W, Morris PJ, Wood KJ, PRETRANSPLANT ADMINISTRATION OF A SINGLE DONOR CLASS I MAJOR HISTOCOMPATABILITY COMPLEX MOLECULE IS SUFFICIENT FOR THE INDEFINITE SURVIVAL OF FULLY ALLOGENEIC CARDIAC ALLOGRAFTS. Evidence for linked epitope suppression: 1. Transplantation. 1997;63:1490.","journal-title":"Transplantation"},{"key":"489_CR53","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/BF00364443","volume":"16","author":"D Wernet","year":"1982","unstructured":"Wernet D. Genetic regulation of the antibody response to H-2Db alloantigens in mice. Immunogenetics. 1982;16:71\u201381.","journal-title":"Immunogenetics"},{"key":"489_CR54","doi-asserted-by":"publisher","first-page":"2415","DOI":"10.1097\/TP.0000000000003149","volume":"104","author":"I Koyama","year":"2020","unstructured":"Koyama I, Bashuda H, Uchida K, Seino K, Habu S, Nakajima I, Fuchinoue S, Okumura K, Teraoka S. A clinical trial with adoptive transfer of ex Vivo-induced, Donor-specific Immune-regulatory cells in kidney Transplantation\u2014A second report. Transplantation. 2020;104:2415.","journal-title":"Transplantation"},{"key":"489_CR55","doi-asserted-by":"publisher","first-page":"4632","DOI":"10.4049\/jimmunol.176.8.4632","volume":"176","author":"DC Neujahr","year":"2006","unstructured":"Neujahr DC, Chen C, Huang X, Markmann JF, Cobbold S, Waldmann H, Sayegh MH, Hancock WW, Turka LA. Accelerated memory cell homeostasis during T cell depletion and approaches to overcome it. J Immunol. 2006;176:4632\u20139.","journal-title":"J Immunol"},{"key":"489_CR56","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1016\/j.ekir.2022.04.003","volume":"7","author":"C Lamarche","year":"2022","unstructured":"Lamarche C, Maltzman JS. Chimeric antigen receptor regulatory T cell in transplantation: the future of cell therapy? Kidney Int Rep. 2022;7:1149\u201352.","journal-title":"Kidney Int Rep"},{"key":"489_CR57","doi-asserted-by":"publisher","first-page":"5671","DOI":"10.1182\/blood-2011-02-337097","volume":"118","author":"A Veerapathran","year":"2011","unstructured":"Veerapathran A, Pidala J, Beato F, Yu X-Z, Anasetti C. Ex vivo expansion of human Tregs specific for alloantigens presented directly or indirectly. Blood. 2011;118:5671\u201380.","journal-title":"Blood"},{"key":"489_CR58","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1084\/jem.188.4.619","volume":"188","author":"A Krause","year":"1998","unstructured":"Krause A, Guo H-F, Latouche J-B, Tan C, Cheung N-KV, Sadelain M. Antigen-dependent CD28 signaling selectively enhances survival and proliferation in genetically modified activated human primary T lymphocytes. J Exp Med. 1998;188:619\u201326.","journal-title":"J Exp Med"},{"key":"489_CR59","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1007\/s12272-019-01136-x","volume":"42","author":"Y-H Lee","year":"2019","unstructured":"Lee Y-H, Kim CH. Evolution of chimeric antigen receptor (CAR) T cell therapy: current status and future perspectives. Arch Pharm Res. 2019;42:607\u201316.","journal-title":"Arch Pharm Res"},{"key":"489_CR60","doi-asserted-by":"publisher","first-page":"e003354","DOI":"10.1136\/jitc-2021-003354","volume":"9","author":"E Roselli","year":"2021","unstructured":"Roselli E, Boucher JC, Li G, et al. 4-1BB and optimized CD28 co-stimulation enhances function of human mono-specific and bi-specific third-generation CAR T cells. J Immunother Cancer. 2021;9:e003354.","journal-title":"J Immunother Cancer"},{"key":"489_CR61","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/j.ymthe.2005.04.016","volume":"12","author":"MA Pul\u00e8","year":"2005","unstructured":"Pul\u00e8 MA, Straathof KC, Dotti G, Heslop HE, Rooney CM, Brenner MK. A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells. Mol Ther. 2005;12:933\u201341.","journal-title":"Mol Ther"},{"key":"489_CR62","unstructured":"Center for Biologics Evaluation and Research. ABECMA (idecabtagene vicleucel) approval letter. U.S. Food & Drug Administration; 2024."},{"key":"489_CR63","unstructured":"Center for Biologics Evaluation and Research. BREYANZI (lisocabtagene maraleucel) approval letter. U.S. Food & Drug Administration; 2024."},{"key":"489_CR64","unstructured":"Center for Biologics Evaluation and Research. KYMRIAH (tisagenlecleucel) approval letter. U.S. Food & Drug Administration; 2024."},{"key":"489_CR65","unstructured":"Center for Biologics Evaluation and Research. TECARTUS (brexucabtagene autoleucel) approval letter. U.S. Food & Drug Administration; 2024."},{"key":"489_CR66","unstructured":"Center for Biologics Evaluation and Research. YESCARTA (axicabtagene ciloleucel) approval letter. U.S. Food & Drug Administration; 2024."},{"key":"489_CR67","unstructured":"Center for Biologics Evaluation and Research. CARVYKTI (ciltacabtagene autoleucel) approval letter. U.S. Food & Drug Administration; 2024."},{"key":"489_CR68","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.1111\/ajt.17063","volume":"22","author":"JC Wagner","year":"2022","unstructured":"Wagner JC, Ronin E, Ho P, Peng Y, Tang Q. Anti-HLA-A2-CAR Tregs prolong vascularized mouse heterotopic heart allograft survival. Am J Transplant. 2022;22:2237\u201345.","journal-title":"Am J Transplant"},{"key":"489_CR69","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1111\/ajt.14185","volume":"17","author":"DA Boardman","year":"2017","unstructured":"Boardman DA, Philippeos C, Fruhwirth GO, et al. Expression of a chimeric antigen receptor specific for donor HLA class I enhances the potency of human regulatory T cells in preventing human skin transplant rejection. Am J Transpl. 2017;17:931\u201343.","journal-title":"Am J Transpl"},{"key":"489_CR70","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1016\/j.ekir.2022.03.030","volume":"7","author":"K Schreeb","year":"2022","unstructured":"Schreeb K, Culme-Seymour E, Ridha E, Dumont C, Atkinson G, Hsu B, Reinke P. Study design: human leukocyte antigen class I molecule A\u221702-Chimeric antigen receptor regulatory T cells in renal transplantation. Kidney Int Rep. 2022;7:1258\u201367.","journal-title":"Kidney Int Rep"},{"key":"489_CR71","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.1111\/ajt.15787","volume":"20","author":"A Sicard","year":"2020","unstructured":"Sicard A, Lamarche C, Speck M, Wong M, Rosado-S\u00e1nchez I, Blois M, Glaichenhaus N, Mojibian M, Levings MK. Donor-specific chimeric antigen receptor Tregs limit rejection in Naive but not sensitized allograft recipients. Am J Transplant. 2020;20:1562\u201373.","journal-title":"Am J Transplant"},{"key":"489_CR72","first-page":"e168601","volume":"133","author":"JA Spanier","year":"2023","unstructured":"Spanier JA, Fung V, Wardell CM, et al. Tregs with an MHC class II peptide-specific chimeric antigen receptor prevent autoimmune diabetes in mice. J Clin Invest. 2023;133:e168601.","journal-title":"J Clin Invest"},{"key":"489_CR73","doi-asserted-by":"publisher","first-page":"eabo0777","DOI":"10.1126\/sciimmunol.abo0777","volume":"7","author":"J Yi","year":"2022","unstructured":"Yi J, Miller AT, Archambault AS, et al. Antigen-specific depletion of CD4 + T cells by CAR T cells reveals distinct roles of higher- and lower-affinity TCRs during autoimmunity. Sci Immunol. 2022;7:eabo0777.","journal-title":"Sci Immunol"},{"key":"489_CR74","doi-asserted-by":"publisher","first-page":"28950","DOI":"10.1073\/pnas.2012495117","volume":"117","author":"S Kobayashi","year":"2020","unstructured":"Kobayashi S, Thelin MA, Parrish HL, Deshpande NR, Lee MS, Karimzadeh A, Niewczas MA, Serwold T, Kuhns MS. A biomimetic five-module chimeric antigen receptor (5MCAR) designed to target and eliminate antigen-specific T cells. Proc Natl Acad Sci U S A. 2020;117:28950\u20139.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"489_CR75","doi-asserted-by":"publisher","first-page":"16","DOI":"10.4049\/jimmunol.2100643","volume":"208","author":"KB Whittington","year":"2022","unstructured":"Whittington KB, Prislovsky A, Beaty J, Albritton L, Radic M, Rosloniec EF. CD8 + T cells expressing an HLA-DR1 chimeric antigen receptor target autoimmune CD4 + T cells in an antigen-Specific manner and inhibit the development of autoimmune arthritis. J Immunol. 2022;208:16\u201326.","journal-title":"J Immunol"},{"key":"489_CR76","doi-asserted-by":"publisher","first-page":"2660","DOI":"10.1016\/j.ymthe.2021.04.034","volume":"29","author":"J Rana","year":"2021","unstructured":"Rana J, Perry DJ, Kumar SRP, Mu\u00f1oz-Melero M, Saboungi R, Brusko TM, Biswas M. CAR- and TRuC-redirected regulatory T cells differ in capacity to control adaptive immunity to FVIII. Mol Ther. 2021;29:2660\u201376.","journal-title":"Mol Ther"},{"key":"489_CR77","doi-asserted-by":"publisher","first-page":"103057","DOI":"10.1016\/j.jaut.2023.103057","volume":"138","author":"P Henschel","year":"2023","unstructured":"Henschel P, Landwehr-Kenzel S, Engels N, et al. Supraphysiological FOXP3 expression in human CAR-Tregs results in improved stability, efficacy, and safety of CAR-Treg products for clinical application. J Autoimmun. 2023;138:103057.","journal-title":"J Autoimmun"},{"key":"489_CR78","doi-asserted-by":"publisher","first-page":"686439","DOI":"10.3389\/fimmu.2021.686439","volume":"12","author":"YD Muller","year":"2021","unstructured":"Muller YD, Ferreira LMR, Ronin E, et al. Precision engineering of an Anti-HLA-A2 chimeric antigen receptor in regulatory T cells for transplant immune tolerance. Front Immunol. 2021;12:686439.","journal-title":"Front Immunol"},{"key":"489_CR79","doi-asserted-by":"publisher","first-page":"eadm8859","DOI":"10.1126\/scitranslmed.adm8859","volume":"16","author":"P Ho","year":"2024","unstructured":"Ho P, Cahir-McFarland E, Fontenot JD, Lodie T, Nada A, Tang Q, Turka LA, Bluestone JA. Harnessing regulatory T cells to Establish immune tolerance. Sci Transl Med. 2024;16:eadm8859.","journal-title":"Sci Transl Med"},{"key":"489_CR80","doi-asserted-by":"publisher","first-page":"2713","DOI":"10.1097\/TP.0000000000001698","volume":"101","author":"C Lamarche","year":"2017","unstructured":"Lamarche C, Orio J, Georges-Tobar V, Pincez T, Goupil M, Dahmani A, Carli C, Brasey A, Busque L, Delisle J-S. Clinical-Scale rapid autologous BK Virus-Specific T cell line generation from kidney transplant recipients with active viremia for adoptive immunotherapy. Transplantation. 2017;101:2713\u201321.","journal-title":"Transplantation"},{"key":"489_CR81","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1056\/NEJM199510193331603","volume":"333","author":"EA Walter","year":"1995","unstructured":"Walter EA, Greenberg PD, Gilbert MJ, Finch RJ, Watanabe KS, Thomas ED, Riddell SR. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med. 1995;333:1038\u201344.","journal-title":"N Engl J Med"},{"key":"489_CR82","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/S0140-6736(95)91150-2","volume":"345","author":"CM Rooney","year":"1995","unstructured":"Rooney CM, Smith CA, Ng CY, Loftin S, Li C, Krance RA, Brenner MK, Heslop HE. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. Lancet. 1995;345:9\u201313.","journal-title":"Lancet"},{"key":"489_CR83","doi-asserted-by":"publisher","first-page":"2644","DOI":"10.1182\/blood-2011-08-371971","volume":"119","author":"E Doubrovina","year":"2012","unstructured":"Doubrovina E, Oflaz-Sozmen B, Prockop SE, et al. Adoptive immunotherapy with unselected or EBV-specific T cells for biopsy-proven EBV + lymphomas after allogeneic hematopoietic cell transplantation. Blood. 2012;119:2644\u201356.","journal-title":"Blood"},{"key":"489_CR84","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1016\/S0140-6736(03)14634-X","volume":"362","author":"KS Peggs","year":"2003","unstructured":"Peggs KS, Verfuerth S, Pizzey A, Khan N, Guiver M, Moss PA, Mackinnon S. Adoptive cellular therapy for early cytomegalovirus infection after allogeneic stem-cell transplantation with virus-specific T-cell lines. Lancet. 2003;362:1375\u20137.","journal-title":"Lancet"},{"key":"489_CR85","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1182\/blood-2006-12-063008","volume":"110","author":"T Haque","year":"2007","unstructured":"Haque T, Wilkie GM, Jones MM, et al. Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial. Blood. 2007;110:1123\u201331.","journal-title":"Blood"},{"key":"489_CR86","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1038\/mt.2013.151","volume":"21","author":"U Gerdemann","year":"2013","unstructured":"Gerdemann U, Katari UL, Papadopoulou A, et al. Safety and clinical efficacy of rapidly-generated trivirus-directed T cells as treatment for adenovirus, EBV, and CMV infections after allogeneic hematopoietic stem cell transplant. Mol Ther. 2013;21:2113\u201321.","journal-title":"Mol Ther"},{"key":"489_CR87","doi-asserted-by":"publisher","first-page":"5113","DOI":"10.1182\/blood-2013-02-486324","volume":"121","author":"AM Leen","year":"2013","unstructured":"Leen AM, Bollard CM, Mendizabal AM, et al. Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation. Blood. 2013;121:5113\u201323.","journal-title":"Blood"},{"key":"489_CR88","doi-asserted-by":"publisher","first-page":"3547","DOI":"10.1200\/JCO.2017.73.0655","volume":"35","author":"I Tzannou","year":"2017","unstructured":"Tzannou I, Papadopoulou A, Naik S, et al. Off-the-Shelf Virus-Specific T cells to treat BK virus, human herpesvirus 6, cytomegalovirus, Epstein-Barr virus, and adenovirus infections after allogeneic hematopoietic Stem-Cell transplantation. J Clin Oncol. 2017;35:3547\u201357.","journal-title":"J Clin Oncol"},{"key":"489_CR89","doi-asserted-by":"publisher","first-page":"e14296","DOI":"10.1111\/tid.14296","volume":"26","author":"B Obermaier","year":"2024","unstructured":"Obermaier B, Braun C, Hensen L, Ahmad O, Faul C, Lang P, Bethge W, Lengerke C, Vogel W. Adenovirus- and cytomegalovirus-specific adoptive T-cell therapy in the context of hematologic cell transplant or HIV infection \u2013 A single-center experience. Transpl Infect Disease. 2024;26:e14296.","journal-title":"Transpl Infect Disease"},{"key":"489_CR90","doi-asserted-by":"crossref","unstructured":"Prockop S, Doubrovina E, Suser S et al. Off-the-shelf EBV-specific T cell immunotherapy for rituximab-refractory EBV-associated lymphoma following transplantation. J Clin Invest 130:733\u201347.","DOI":"10.1172\/JCI121127"},{"key":"489_CR91","doi-asserted-by":"publisher","first-page":"e14179","DOI":"10.1111\/tid.14179","volume":"25","author":"M Anand","year":"2023","unstructured":"Anand M, Nysather J, McGraw G, Apewokin S, Khoury R, Grimley MS, Bumb S, Govil A. Viral specific T cell therapy in kidney transplant recipients \u2013 A single-center experience. Transpl Infect Disease. 2023;25:e14179.","journal-title":"Transpl Infect Disease"},{"key":"489_CR92","doi-asserted-by":"publisher","first-page":"2710","DOI":"10.1200\/JCO.20.02608","volume":"39","author":"A Olson","year":"2021","unstructured":"Olson A, Lin R, Marin D, et al. Third-Party BK Virus-Specific cytotoxic T lymphocyte therapy for hemorrhagic cystitis following allotransplantation. J Clin Oncol. 2021;39:2710\u20139.","journal-title":"J Clin Oncol"},{"key":"489_CR93","doi-asserted-by":"crossref","unstructured":"Rubinstein JD, Jodele S, Heyenbruch D et al. (2022) Off-the-Shelf Third-Party Virus-Specific T Cell Therapy to Treat JC Polyomavirus Infection in Hematopoietic Stem Cell Transplantation Recipients. Transplant Cell Ther 28:116.e1-116.e7.","DOI":"10.1016\/j.jtct.2021.11.005"},{"key":"489_CR94","unstructured":"Feuchtinger PT. (2023) Treatment of Chemo-refractory viral infections after allogeneic stem cell transplantation with multispecific T cells against CMV, EBV and adv: A phase III, prospective, multicentre clinical trial. clinicaltrials.gov."},{"key":"489_CR95","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-2415","author":"T Pfeiffer","year":"2023","unstructured":"Pfeiffer T, Tzannou I, M W, et al. Posoleucel, an allogeneic, Off-the-Shelf Multivirus-Specific T-Cell therapy, for the treatment of refractory viral infections in the Post-HCT setting. Clin Cancer Res. 2023. https:\/\/doi.org\/10.1158\/1078-0432.CCR-22-2415.","journal-title":"Clin Cancer Res"},{"key":"489_CR96","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1681\/ASN.0000000000000329","volume":"35","author":"A Chandraker","year":"2024","unstructured":"Chandraker A, Regmi A, Gohh R, et al. Posoleucel in kidney transplant recipients with BK viremia: multicenter, randomized, Double-Blind, Placebo-Controlled phase 2 trial. J Am Soc Nephrol. 2024;35:618\u201329.","journal-title":"J Am Soc Nephrol"},{"key":"489_CR97","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1016\/j.ajt.2024.04.009","volume":"24","author":"R Khoury","year":"2024","unstructured":"Khoury R, Grimley MS, Nelson AS, et al. Third-party virus-specific T cells for the treatment of double-stranded DNA viral reactivation and posttransplant lymphoproliferative disease after solid organ transplant. Am J Transplant. 2024;24:1634\u201343.","journal-title":"Am J Transplant"},{"key":"489_CR98","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/S1046-2023(03)00125-7","volume":"31","author":"JDM Campbell","year":"2003","unstructured":"Campbell JDM. Detection and enrichment of antigen-specific CD4 + and CD8 + T cells based on cytokine secretion. Methods. 2003;31:150\u20139.","journal-title":"Methods"},{"key":"489_CR99","doi-asserted-by":"publisher","first-page":"4053","DOI":"10.1002\/(SICI)1521-4141(199912)29:12<4053::AID-IMMU4053>3.0.CO;2-C","volume":"29","author":"H Brosterhus","year":"1999","unstructured":"Brosterhus H, Brings S, Leyendeckers H, Manz RA, Miltenyi S, Radbruch A, Assenmacher M, Schmitz J. Enrichment and detection of live antigen-specific CD4(+) and CD8(+) T cells based on cytokine secretion. Eur J Immunol. 1999;29:4053\u20139.","journal-title":"Eur J Immunol"},{"key":"489_CR100","first-page":"5745","volume":"4","author":"AS Nelson","year":"2020","unstructured":"Nelson AS, Heyenbruch D, Rubinstein JD, et al. Virus-specific T-cell therapy to treat BK polyomavirus infection in bone marrow and solid organ transplant recipients. Blood Adv. 2020;4:5745\u201354.","journal-title":"Blood Adv"},{"key":"489_CR101","doi-asserted-by":"publisher","first-page":"ra24283","DOI":"10.1126\/scitranslmed.3008825","volume":"6","author":"A Papadopoulou","year":"2014","unstructured":"Papadopoulou A, Gerdemann U, Katari UL, et al. Activity of Broad-Spectrum T cells as treatment for adv, EBV, CMV, BKV, and HHV6 infections after HSCT. Sci Transl Med. 2014;6:ra24283\u201324283.","journal-title":"Sci Transl Med"},{"key":"489_CR102","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1097\/MOH.0000000000000461","volume":"25","author":"E Migliori","year":"2018","unstructured":"Migliori E, Chang M, Muranski P. Restoring antiviral immunity with adoptive transfer of ex-vivo generated T cells. Curr Opin Hematol. 2018;25:486\u201393.","journal-title":"Curr Opin Hematol"},{"key":"489_CR103","doi-asserted-by":"publisher","first-page":"393","DOI":"10.3389\/fimmu.2016.00393","volume":"7","author":"C Priesner","year":"2016","unstructured":"Priesner C, Esser R, Tischer S, et al. Comparative analysis of Clinical-Scale IFN-\u03b3-Positive T-Cell enrichment using partially and fully integrated platforms. Front Immunol. 2016;7:393.","journal-title":"Front Immunol"},{"key":"489_CR104","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1200\/JCO.2011.39.8495","volume":"31","author":"V Icheva","year":"2013","unstructured":"Icheva V, Kayser S, Wolff D, et al. Adoptive transfer of Epstein-Barr virus (EBV) nuclear antigen 1\u2013Specific T cells as treatment for EBV reactivation and lymphoproliferative disorders after allogeneic Stem-Cell transplantation. JCO. 2013;31:39\u201348.","journal-title":"JCO"},{"key":"489_CR105","doi-asserted-by":"publisher","first-page":"1986","DOI":"10.1182\/blood-2014-06-573725","volume":"125","author":"J Feucht","year":"2015","unstructured":"Feucht J, Opherk K, Lang P, et al. Adoptive T-cell therapy with hexon-specific Th1 cells as a treatment of refractory adenovirus infection after HSCT. Blood. 2015;125:1986\u201394.","journal-title":"Blood"},{"key":"489_CR106","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","volume":"124","author":"DW Lee","year":"2014","unstructured":"Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014;124:188\u201395.","journal-title":"Blood"},{"key":"489_CR107","doi-asserted-by":"crossref","unstructured":"Parajuli S, Jorgenson M, Meyers RO, Djamali A, Galipeau J. (2021) Role of Virus-Specific T cell therapy for cytomegalovirus and BK infections in kidney transplant recipients. Kidney360 2:905\u201315.","DOI":"10.34067\/KID.0001572021"},{"key":"489_CR108","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1111\/j.1365-2141.2006.06108.x","volume":"134","author":"T Feuchtinger","year":"2006","unstructured":"Feuchtinger T, Matthes-Martin S, Richard C, et al. Safe adoptive transfer of virus-specific T-cell immunity for the treatment of systemic adenovirus infection after allogeneic stem cell transplantation. Br J Haematol. 2006;134:64\u201376.","journal-title":"Br J Haematol"},{"key":"489_CR109","doi-asserted-by":"publisher","first-page":"4360","DOI":"10.1182\/blood-2010-01-262089","volume":"116","author":"T Feuchtinger","year":"2010","unstructured":"Feuchtinger T, Opherk K, Bethge WA, et al. Adoptive transfer of pp65-specific T cells for the treatment of chemorefractory cytomegalovirus disease or reactivation after haploidentical and matched unrelated stem cell transplantation. Blood. 2010;116:4360\u20137.","journal-title":"Blood"},{"key":"489_CR110","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1182\/bloodadvances.2022008219","volume":"7","author":"H Kinoshita","year":"2023","unstructured":"Kinoshita H, Mandava M, Jensen-Wachspress M, et al. Outcomes following posttransplant virus-specific T-cell therapy in patients with sickle cell disease. Blood Adv. 2023;7:2105\u201316.","journal-title":"Blood Adv"},{"key":"489_CR111","doi-asserted-by":"publisher","first-page":"2433","DOI":"10.1016\/j.bbmt.2018.08.024","volume":"24","author":"B Withers","year":"2018","unstructured":"Withers B, Clancy L, Burgess J, Simms R, Brown R, Micklethwaite K, Blyth E, Gottlieb D. Establishment and operation of a Third-Party Virus-Specific T cell bank within an allogeneic stem cell transplant program. Biol Blood Marrow Transpl. 2018;24:2433\u201342.","journal-title":"Biol Blood Marrow Transpl"},{"key":"489_CR112","doi-asserted-by":"publisher","first-page":"e15419","DOI":"10.1111\/tan.15419","volume":"103","author":"F Rudilla","year":"2024","unstructured":"Rudilla F, Carrasco-Benso MP, Pasamar H, et al. Development and characterization of a cell donor registry for virus-specific T cell manufacture in a blood bank. HLA. 2024;103:e15419.","journal-title":"HLA"},{"key":"489_CR113","first-page":"305","volume":"29","author":"TJ Galletta","year":"2023","unstructured":"Galletta TJ, Lane A, Lutzko C, et al. Third-Party and Patient-Specific Donor-Derived Virus-Specific T cells demonstrate similar efficacy and safety for management of viral infections after hematopoietic stem cell transplantation in children and young adults. Transpl Cell Ther. 2023;29:305\u201310.","journal-title":"Transpl Cell Ther"},{"key":"489_CR114","doi-asserted-by":"publisher","first-page":"e165476","DOI":"10.1172\/JCI165476","volume":"133","author":"SE Prockop","year":"2023","unstructured":"Prockop SE, Hasan A, Doubrovina E, et al. Third-party cytomegalovirus-specific T cells improved survival in refractory cytomegalovirus viremia after hematopoietic transplant. J Clin Invest. 2023;133:e165476.","journal-title":"J Clin Invest"},{"key":"489_CR115","doi-asserted-by":"publisher","first-page":"1289313","DOI":"10.3389\/fimmu.2023.1289313","volume":"14","author":"DG Sausen","year":"2023","unstructured":"Sausen DG, Poirier MC, Spiers LM, Smith EN. Mechanisms of T cell evasion by Epstein-Barr virus and implications for tumor survival. Front Immunol. 2023;14:1289313.","journal-title":"Front Immunol"},{"key":"489_CR116","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1089\/088282403763635401","volume":"16","author":"MFC Callan","year":"2003","unstructured":"Callan MFC. The evolution of antigen-specific CD8 + T cell responses after natural primary infection of humans with Epstein-Barr virus. Viral Immunol. 2003;16:3\u201316.","journal-title":"Viral Immunol"},{"key":"489_CR117","doi-asserted-by":"publisher","first-page":"10391","DOI":"10.1073\/pnas.96.18.10391","volume":"96","author":"R Khanna","year":"1999","unstructured":"Khanna R, Bell S, Sherritt M, et al. Activation and adoptive transfer of Epstein-Barr virus-specific cytotoxic T cells in solid organ transplant patients with posttransplant lymphoproliferative disease. Proc Natl Acad Sci U S A. 1999;96:10391\u20136.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"489_CR118","doi-asserted-by":"publisher","first-page":"e356","DOI":"10.3324\/haematol.2018.207548","volume":"104","author":"S Kazi","year":"2019","unstructured":"Kazi S, Mathur A, Wilkie G, et al. Long-term follow up after third-party viral-specific cytotoxic lymphocytes for immunosuppression- and Epstein-Barr virus-associated lymphoproliferative disease. Haematologica. 2019;104:e356\u20139.","journal-title":"Haematologica"},{"key":"489_CR119","doi-asserted-by":"publisher","first-page":"2483","DOI":"10.1111\/tri.14107","volume":"34","author":"J-Y Liu","year":"2021","unstructured":"Liu J-Y, Zhang J-M, Zhan H-S, Sun L-Y, Wei L. EBV-specific cytotoxic T lymphocytes for refractory EBV-associated post-transplant lymphoproliferative disorder in solid organ transplant recipients: a systematic review. Transpl Int. 2021;34:2483\u201393.","journal-title":"Transpl Int"},{"key":"489_CR120","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1016\/S1470-2045(23)00649-6","volume":"25","author":"KM Mahadeo","year":"2024","unstructured":"Mahadeo KM, Baiocchi R, Beitinjaneh A, et al. Tabelecleucel for allogeneic Haematopoietic stem-cell or solid organ transplant recipients with Epstein-Barr virus-positive post-transplant lymphoproliferative disease after failure of rituximab or rituximab and chemotherapy (ALLELE): a phase 3, multicentre, open-label trial. Lancet Oncol. 2024;25:376\u201387.","journal-title":"Lancet Oncol"},{"key":"489_CR121","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1182\/bloodadvances.2023010832","volume":"8","author":"B Wistinghausen","year":"2024","unstructured":"Wistinghausen B, Toner K, Barkauskas DA, et al. Durable immunity to EBV after rituximab and third-party LMP-specific T cells: a children\u2019s oncology group study. Blood Adv. 2024;8:1116\u201327.","journal-title":"Blood Adv"},{"key":"489_CR122","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1093\/cid\/ciy549","volume":"68","author":"C Smith","year":"2019","unstructured":"Smith C, Beagley L, Rehan S, et al. Autologous adoptive T-cell therapy for recurrent or Drug-resistant cytomegalovirus complications in solid organ transplant recipients: A Single-arm Open-label phase I clinical trial. Clin Infect Dis. 2019;68:632\u201340.","journal-title":"Clin Infect Dis"},{"key":"489_CR123","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1159\/000501460","volume":"5","author":"H Su","year":"2019","unstructured":"Su H, Zhang C-Y, Lin J-H, Hammes H-P, Zhang C. The role of Long-Lived plasma cells in antibody-Mediated rejection of kidney transplantation: an update. Kidney Dis (Basel). 2019;5:211\u20139.","journal-title":"Kidney Dis (Basel)"},{"key":"489_CR124","doi-asserted-by":"publisher","first-page":"101336","DOI":"10.1016\/j.xcrm.2023.101336","volume":"4","author":"Z Zhang","year":"2023","unstructured":"Zhang Z, Markmann C, Yu M, et al. Immunotherapy targeting B cells and long-lived plasma cells effectively eliminates pre-existing donor-specific allo-antibodies. Cell Rep Med. 2023;4:101336.","journal-title":"Cell Rep Med"},{"key":"489_CR125","doi-asserted-by":"publisher","first-page":"109432","DOI":"10.1016\/j.celrep.2021.109432","volume":"36","author":"R Basar","year":"2021","unstructured":"Basar R, Uprety N, Ensley E, et al. Generation of glucocorticoid-resistant SARS-CoV-2 T cells for adoptive cell therapy. Cell Rep. 2021;36:109432.","journal-title":"Cell Rep"},{"key":"489_CR126","doi-asserted-by":"publisher","first-page":"3357","DOI":"10.1182\/bloodadvances.2020001977","volume":"4","author":"R Basar","year":"2020","unstructured":"Basar R, Daher M, Uprety N, et al. Large-scale GMP-compliant CRISPR-Cas9-mediated deletion of the glucocorticoid receptor in multivirus-specific T cells. Blood Adv. 2020;4:3357\u201367.","journal-title":"Blood Adv"}],"container-title":["Current Transplantation Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40472-025-00489-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40472-025-00489-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40472-025-00489-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T05:19:21Z","timestamp":1767676761000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40472-025-00489-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,23]]},"references-count":126,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["489"],"URL":"https:\/\/doi.org\/10.1007\/s40472-025-00489-1","relation":{},"ISSN":["2196-3029"],"issn-type":[{"value":"2196-3029","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,23]]},"assertion":[{"value":"21 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}},{"value":"The authors report no conflict of interests related to the topics presented in this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"33"}}